What it's for (Indications)
- Rifaximin is an antimicrobial agent primarily indicated for several gastrointestinal conditions where localized action is beneficial due to its minimal systemic absorption.
- It is approved for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults.
- For this indication, rifaximin aims to reduce symptoms including abdominal pain and loose or watery stools by modulating the gut microbiota.
- Additionally, rifaximin is indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
- In HE, it works to decrease ammonia-producing bacteria in the gut, thereby reducing the production and absorption of neurotoxins.
- Furthermore, it is approved for the treatment of traveler's diarrhea (TD) caused by non-invasive strains of Escherichia coli in adults and adolescents aged 12 years and older.
- These indications leverage rifaximin's targeted action within the gastrointestinal lumen, providing therapeutic benefits for conditions influenced by gut flora imbalances or pathogenic bacterial overgrowth.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of rifaximin varies significantly depending on the specific indication. For Irritable Bowel Syndrome with Diarrhea (IBS-D), the recommended adult dosage is 550 mg taken orally three times daily for a 14-day course. Repeat courses may be considered for symptom recurrence. For the reduction in risk of overt hepatic encephalopathy (HE) recurrence, the recommended adult dosage is 550 mg taken orally two times daily, on an ongoing basis. For traveler's diarrhea (TD) caused by non-invasive strains of Escherichia coli, the recommended dosage for adults and adolescents 12 years of age and older is 200 mg taken orally three times daily for 3 days. Rifaximin can be administered with or without food. No dosage adjustment is generally required for patients with hepatic impairment for the treatment of hepatic encephalopathy. However, caution is advised for patients with severe hepatic impairment when used for other indications due to potential for increased systemic exposure. Adherence to the prescribed dosage and duration is crucial for optimizing therapeutic outcomes and minimizing potential adverse effects. |
Safety & Warnings
Common Side Effects
- Rifaximin, while generally well-tolerated due to its low systemic absorption, can cause various side effects.
- Common adverse reactions reported across its indications include peripheral edema, nausea, dizziness, fatigue, and headache.
- For patients treated for Irritable Bowel Syndrome with Diarrhea (IBS-D), abdominal pain and flatulence are also frequently reported.
- In the context of hepatic encephalopathy, common side effects include ascites, peripheral edema, nausea, and dizziness.
- More serious, albeit less common, adverse effects can occur.
- These include hypersensitivity reactions such as anaphylaxis, angioedema, dermatitis, rash, and pruritus, necessitating immediate medical attention if experienced.
- Furthermore, like many antimicrobial agents, rifaximin carries a risk of *Clostridioides difficile*-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis.
- Other potential concerns include the development of bacterial resistance, particularly with prolonged or repeated courses of therapy, and superinfection with non-susceptible organisms.
- Patients should be counseled on recognizing and reporting any concerning symptoms to their healthcare provider.
Serious Warnings
- Black Box Warning: Rifaximin (e.g., Zerifax) does not carry a specific Black Box Warning from the U.S. Food and Drug Administration (FDA). However, it is crucial for healthcare professionals and patients to be aware of certain serious warnings that warrant careful consideration during treatment. While not a formal 'boxed warning,' the potential for *Clostridioides difficile*-associated diarrhea (CDAD) is a significant safety concern, as it has been reported with nearly all antibacterial agents, including rifaximin. CDAD can range in severity from mild diarrhea to fatal colitis, and its onset can occur during or several weeks after antibiotic treatment. Prompt diagnosis and appropriate management are essential if CDAD is suspected. Additionally, hypersensitivity reactions, including anaphylaxis and angioedema, though rare, are serious and require immediate discontinuation of the drug. Patients should be advised about the signs and symptoms of these serious conditions and instructed to seek immediate medical attention if they occur.
- Several important warnings and precautions are associated with rifaximin use.
- A significant concern is the potential for *Clostridioides difficile*-associated diarrhea (CDAD), which has been reported with nearly all antibacterial agents, including rifaximin.
- Healthcare professionals should consider CDAD in all patients who present with diarrhea following antibacterial drug use.
- If CDAD is suspected or confirmed, rifaximin should be discontinued, and appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of *C.
- difficile*, and surgical evaluation should be instituted as clinically indicated.
- Rifaximin's minimal systemic absorption means it is not effective for systemic bacterial infections and should not be used in such cases.
- For traveler's diarrhea, rifaximin is not effective for diarrhea complicated by fever and/or bloody stools, or for diarrhea caused by pathogens other than non-invasive Escherichia coli.
- Its use in these situations may lead to worsening of symptoms or treatment failure.
- Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, requiring immediate discontinuation upon occurrence.
- The long-term effects of repeated courses for IBS-D are not fully established, and bacterial resistance development remains a theoretical concern with extended or recurrent exposure.
How it Works (Mechanism of Action)
Rifaximin is a non-systemic oral antibiotic belonging to the rifamycin class of antimicrobials. Its primary mechanism of action involves inhibiting bacterial RNA synthesis. Rifaximin achieves this by irreversibly binding to the beta subunit of bacterial DNA-dependent RNA polymerase, thereby blocking the enzyme's activity and subsequently inhibiting bacterial transcription and protein synthesis. This results in bactericidal activity against susceptible organisms. A critical aspect of rifaximin's pharmacology is its extremely low systemic absorption from the gastrointestinal tract, typically less than 0.4%. This low absorption ensures that the drug remains largely confined to the intestinal lumen, where it exerts its local antimicrobial effects. In hepatic encephalopathy, rifaximin reduces the numbers of ammonia-producing bacteria in the gut, decreasing the production and absorption of neurotoxins, particularly ammonia. For IBS-D, it helps normalize the gut microbiota, reducing bacterial overgrowth and associated symptoms. For traveler's diarrhea, it directly targets susceptible pathogenic bacteria within the intestine.